Sector
PharmaceuticalsOpen
₹1,050.05Prev. Close
₹1,054.75Turnover(Lac.)
₹6.06Day's High
₹1,068.05Day's Low
₹1,05052 Week's High
₹1,749.6552 Week's Low
₹589.2Book Value
₹644.74Face Value
₹10Mkt Cap (₹ Cr.)
317.48P/E
12.89EPS
81.46Divi. Yield
0.14Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 3.02 | 3.02 | 3.02 | 3.02 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 173.2 | 161 | 148.19 | 123.31 |
Net Worth | 176.22 | 164.02 | 151.21 | 126.33 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Revenue | 260.25 | 256.92 | 344.15 | 212.98 |
yoy growth (%) | 1.29 | -25.34 | 61.58 | -1.34 |
Raw materials | -139.65 | -162.04 | -230.28 | -132.95 |
As % of sales | 53.66 | 63.07 | 66.91 | 62.42 |
Employee costs | -27.11 | -23.27 | -20.63 | -17.64 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 19.35 | 13.33 | 23.75 | 6.39 |
Depreciation | -7.21 | -7.24 | -5.76 | -5.7 |
Tax paid | -6.18 | -4.19 | -7.12 | 0.1 |
Working capital | 6.74 | 5.62 | 4.3 | 1.01 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 1.29 | -25.34 | 61.58 | -1.34 |
Op profit growth | 25 | -26.72 | 145.88 | -53.6 |
EBIT growth | 29.45 | -36.93 | 176.29 | -57.05 |
Net profit growth | 43.95 | -45 | 155.84 | -49.77 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 305.96 | 315.56 | 349.74 | 265.59 | 260.78 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 305.96 | 315.56 | 349.74 | 265.59 | 260.78 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 3.83 | 5.42 | 14.76 | 1.78 | 2.28 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,683.45 | 128.24 | 4,04,012.02 | 1,181.05 | 0.8 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,620.45 | 71.97 | 1,49,188.03 | 594 | 0.53 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,461.9 | 25.36 | 1,18,041 | 1,438.15 | 0.89 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,056.05 | 56.74 | 1,03,507.2 | 485 | 0.92 | 2,330 | 222.38 |
Dr Reddys Laboratories Ltd DRREDDY | 1,107.95 | 17.83 | 92,443.89 | 849.4 | 0.72 | 4,997.8 | 322.46 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director
T V V S N Murthy
Independent Director
P Sarath Kumar
Company Sec. & Compli. Officer
Trupti Ranjan Mohanty
Executive Director
Talluri Venkata Praveen
Whole-time Director
Sudeepthi Gopin eedi
Independent Director
Mannam Malakondaiah
Independent Director
Srinivas Samavedam
Independent Director
P Venkata Subbarao
Additional Director
Sundaramma Patibandla
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by SMS Lifesciences India Ltd
Summary
SMS Lifesciences India Limited was incorporated originally as Potluri Real Estate Private Limited on May 31, 2006. The Companys name was changed to Potluri Packaging Industries Private Limited on 6 November, 2013 and again changed to SMS Lifesciences India Private Limited on 4 August, 2014 to undertake the activities related pharma sector. The Company became a wholly owned subsidiary Company of SMS Pharmaceuticals Limited w.e.f. 01.04.2016 and subsequently got converted into a Public Limited w.e.f. 22 June, 2016.The Company is engaged in the business of manufacturing and export of Active Pharma Ingredients(APIs) and their intermediates. The Company is having manufacturing facilities at Kazipally and Jeedimetla, Hyderabad with an installed capacity of 65 KL. What started off as a single facility - single product manufacturing company in 1990 grew to be a multi-location group having products spread across an array of therapeutic segments. SMS Group was given the export house status in the year 1997-98.Having three multi product facilities in operation and a research centre, the Company executed contract manufacturing and research assignment for global customer base. The Scheme of Arrangement between SMS Pharmaceuticals Limited with the Company was implemented in 2016-17. Pursuant to the Scheme, the Semi Regulated facilities i.e Unit No. I, IV and V along with premises situated at Industrial Estate, Sanathnagar, Hyderabad; Industrial Development Area, Jeedimetla, Hyderabad; Prem
Read More
The SMS Lifesciences India Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹1050.1 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of SMS Lifesciences India Ltd is ₹317.48 Cr. as of 13 Mar ‘25
The PE and PB ratios of SMS Lifesciences India Ltd is 12.89 and 1.69 as of 13 Mar ‘25
The 52-week high/low is the highest and lowest price at which a SMS Lifesciences India Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of SMS Lifesciences India Ltd is ₹589.2 and ₹1749.65 as of 13 Mar ‘25
SMS Lifesciences India Ltd's CAGR for 5 Years at 37.00%, 3 Years at 13.83%, 1 Year at 74.17%, 6 Month at -34.93%, 3 Month at -12.27% and 1 Month at -16.66%.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.